drugset / Trial / NCT00483561

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00483561 ↗

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gefitinib together with etoposide may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gefitinib together with etoposide works in treating patients with advanced prostate cancer that did not respond to hormone therapy.

Timeline

Start
2004-01
Primary completion
2010-01
Completion
2010-01

Outcome

Outcome not reported

Stopped: “PI left UNMC”

Drugs

EvaluationDrugModalityDoseRoute
Subject Etoposide Small molecule 50 mg/m2 Oral
Subject Gefitinib Small molecule 250 mg Oral

Indications